Under the magic of technology, Elon Musk's Neuralink company has brought new hope to a paralyzed gaming enthusiast named Alex. With brain-computer interface technology, Alex is not only able to play the game 'CS2' but has even achieved a stunning triple kill, something that was unimaginable before.

The rapid development of brain-computer interface technology is reshaping human lives, not only helping patients with speech disorders regain their communication abilities and allowing paralyzed individuals to walk again, but also potentially granting humanity 'superpowers'. Elon Musk's Neuralink company has enabled direct interaction with the digital world by implanting chips in paralyzed patients, allowing them to control devices with their thoughts, bringing unprecedented convenience and possibilities to life. This technology is not limited to assistive functions; it has also sparked discussions about enhancing human capabilities in the future, including the possibility of competing with superintelligent AI.

Neuralink has successfully implanted a brain-computer interface in a second human subject, marking a significant step towards telepathy. The first patient, Noland Arbaugh, demonstrated the technology's potential by controlling a computer with his thoughts. The second patient received 400 electrodes, indicating technological maturity. Elon Musk, in an interview with Lex Fridman, announced plans for at least 8 more implants this year. Neuralink aim....

Tesla CEO Elon Musk has proposed seeking board approval to invest $5 billion in his artificial intelligence startup, xAI. This move may heighten the conflicts of interest between Musk's companies, including SpaceX and Neuralink, which develops brain-computer interfaces. Tesla is transforming into a robotics and AI company, planning to establish a fleet of autonomous 'robotaxis' and humanoid robots powered by this technology. xAI has raised $6 billion and is valued at $18 billion, aiming to catch up with OpenAI and Anthropic.

In the latest news, Musk's brain-computer interface company Neuralink successfully conducted its first human clinical trial, implanting a brain-computer interface device and announcing that the patient has recovered well. This marks a significant advancement for Neuralink in human clinical research since receiving FDA approval last year. The experiment is a step towards Neuralink's exploration of commercialization and represents a milestone in the company's commitment to developing brain-computer interface technology. The company's ultimate goal is to create a full-brain interface, bringing biology and artificial intelligence closer together.

Neuralink is recruiting patients with quadriplegia and ALS for its first human trial. The purpose of the trial is to assess the safety and functionality of the brain-computer interface implantation tool, marking a crucial step in Neuralink's advancement of clinical applications for brain-computer interfaces.